Notice: Function _load_textdomain_just_in_time was called incorrectly. Translation loading for the wordpress-seo domain was triggered too early. This is usually an indicator for some code in the plugin or theme running too early. Translations should be loaded at the init action or later. Please see Debugging in WordPress for more information. (This message was added in version 6.7.0.) in /var/www/html/wp-includes/functions.php on line 6260 Amgen Acquires Turkish Pharma | Contract Pharma

What are you searching for?

Sign in
Breaking News

Amgen Acquires Turkish Pharma

Broadens international expansion strategy

Author Image

By: Tim Wright

Editor-in-Chief, Contract Pharma

Amgen has entered an agreement to acquire 95.6% Mustafa Nevzat Pharmaceuticals (MN), a privately held Turkish pharmaceutical company, for $700 million in cash. MN is a leading supplier of pharmaceuticals to hospitals and a major supplier of injectable medicines in Turkey, and has a successful and growing export business. MN had revenues of approximately $200 million in 2011.

“Amgen is dedicated to making our innovative medicines available to patients in major markets around the world,” said Robert A. Bradway, president and chief operating officer at Amgen. ”Together with MN’s staff and management team, we plan to grow our business with high quality and innovative medicines in Turkey and the surrounding region.”

“This transaction represents an attractive opportunity for MN, its employees and customers,” said Levent Selamoglu, general manager and chief executive officer of MN. “The combination of MN and Amgen creates an innovation leader in Turkey with unique capabilities and scope to expand regionally and in other attractive high-growth markets. Amgen’s focus and resources will also ensure continued investment in Turkey.

Add us as a preferred source on Google

Get the latest Contract Pharma news, insights and analysis in your Google Search and AI experiences.

Add Contract Pharma as a preferred source on Google (opens in a new tab)

Keep Up With Our Content. Subscribe To Contract Pharma Newsletters